REGENXBIO Investors Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Initiation: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the product's safety and efficacy.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating a commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.990
Low
19.00
Averages
29.71
High
45.00
Current: 7.990
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiation: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the product's safety and efficacy.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating a commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against REGENXBIO for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the period from February 9, 2022, to January 27, 2026, with a deadline of April 14, 2026.
- False Statements: The complaint alleges that REGENXBIO made false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, concealing adverse information that led to investor losses during the class period.
- FDA Clinical Hold: The FDA placed a clinical hold on RGX-111 after a trial participant developed a tumor, revealing significant misleading information in the company's public statements that affected investor decisions.
- Investor Rights Protection: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, encouraging affected shareholders to reach out to participate in the lawsuit and seek recovery for their losses.
See More
Class Action Lawsuit Announced for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of REGENXBIO (NASDAQ:RGNX) securities purchasers from February 9, 2022, to January 27, 2026, indicating investor concerns regarding the company's future prospects.
- Compensation Structure: Investors joining the lawsuit will not incur any upfront costs through a contingency fee arrangement, which lowers the barrier for participation and may encourage more affected investors to join the action.
- Case Background: The lawsuit alleges that REGENXBIO provided false and misleading information regarding the development of its RGX-111 gene therapy, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
REGENXBIO Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against REGENXBIO for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Issue: The complaint alleges that REGENXBIO made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study rendered the company's prior public statements false and materially misleading, exacerbating investor damages when the market learned the truth.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
REGENXBIO Faces Class Action Over Misleading Drug Candidate Claims
- Lawsuit Background: Robbins LLP has filed a class action against REGENXBIO (NASDAQ: RGNX), alleging that the company misled investors about the efficacy of its gene therapy RGX-111 between February 9, 2022, and January 27, 2026, resulting in significant investor losses.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 due to preliminary findings of a central nervous system tumor in a participant, raising serious safety concerns and further damaging investor confidence in the drug's viability.
- Stock Price Plunge: Following the FDA's announcement, REGENXBIO's stock price plummeted from $13.41 to $11.01 per share, marking a 17.8% decline in just one day, which reflects a growing pessimism among investors regarding the company's future prospects.
- Investor Action: Affected shareholders can submit their applications by April 14, 2026, to serve as lead plaintiffs in the class action, indicating a strong investor demand for accountability and improved corporate governance practices.
See More
REGENXBIO Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all individuals or entities who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, alleging concealment of adverse facts regarding the RGX-111 trial.
- False Statements Allegation: The complaint claims that defendants provided overly positive statements to investors while disseminating false and misleading information, leading to significant losses when the FDA placed a clinical hold on RGX-111 on January 28, 2026.
- Stock Price Reaction: Following the announcement on January 28, REGENXBIO's stock price plummeted from $13.41 per share on January 27 to $11.01 per share, marking a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Action: Affected investors are urged to contact the law firm before the April 14, 2026 lead plaintiff motion deadline to discuss their rights and interests in the class action, highlighting investor concerns regarding corporate governance and transparency.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiation: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the product's safety and efficacy.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating a commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against REGENXBIO for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the period from February 9, 2022, to January 27, 2026, with a deadline of April 14, 2026.
- False Statements: The complaint alleges that REGENXBIO made false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, concealing adverse information that led to investor losses during the class period.
- FDA Clinical Hold: The FDA placed a clinical hold on RGX-111 after a trial participant developed a tumor, revealing significant misleading information in the company's public statements that affected investor decisions.
- Investor Rights Protection: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, encouraging affected shareholders to reach out to participate in the lawsuit and seek recovery for their losses.
See More
Class Action Lawsuit Announced for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of REGENXBIO (NASDAQ:RGNX) securities purchasers from February 9, 2022, to January 27, 2026, indicating investor concerns regarding the company's future prospects.
- Compensation Structure: Investors joining the lawsuit will not incur any upfront costs through a contingency fee arrangement, which lowers the barrier for participation and may encourage more affected investors to join the action.
- Case Background: The lawsuit alleges that REGENXBIO provided false and misleading information regarding the development of its RGX-111 gene therapy, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
REGENXBIO Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against REGENXBIO for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Issue: The complaint alleges that REGENXBIO made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study rendered the company's prior public statements false and materially misleading, exacerbating investor damages when the market learned the truth.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
REGENXBIO Faces Class Action Over Misleading Drug Candidate Claims
- Lawsuit Background: Robbins LLP has filed a class action against REGENXBIO (NASDAQ: RGNX), alleging that the company misled investors about the efficacy of its gene therapy RGX-111 between February 9, 2022, and January 27, 2026, resulting in significant investor losses.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 due to preliminary findings of a central nervous system tumor in a participant, raising serious safety concerns and further damaging investor confidence in the drug's viability.
- Stock Price Plunge: Following the FDA's announcement, REGENXBIO's stock price plummeted from $13.41 to $11.01 per share, marking a 17.8% decline in just one day, which reflects a growing pessimism among investors regarding the company's future prospects.
- Investor Action: Affected shareholders can submit their applications by April 14, 2026, to serve as lead plaintiffs in the class action, indicating a strong investor demand for accountability and improved corporate governance practices.
See More
REGENXBIO Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all individuals or entities who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, alleging concealment of adverse facts regarding the RGX-111 trial.
- False Statements Allegation: The complaint claims that defendants provided overly positive statements to investors while disseminating false and misleading information, leading to significant losses when the FDA placed a clinical hold on RGX-111 on January 28, 2026.
- Stock Price Reaction: Following the announcement on January 28, REGENXBIO's stock price plummeted from $13.41 per share on January 27 to $11.01 per share, marking a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Action: Affected investors are urged to contact the law firm before the April 14, 2026 lead plaintiff motion deadline to discuss their rights and interests in the class action, highlighting investor concerns regarding corporate governance and transparency.
See More
